Transfusion Medicine Reviews
Volume 23, Issue 3 , Pages 205-220 , July 2009

Selection Criteria to Protect the Blood Donor in North America and Europe: Past (Dogma), Present (Evidence), and Future (Hemovigilance)

References 

  1. Boulton F. Evidence-based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply, and emphasis on the management of donation-induced iron depletion. Transf Med. 2008;18:13–27
  2. Strauss RG. Rationale for medical director acceptance or rejection of allogeneic plateletpheresis donors with underlying medical disorders. J Clin Apheresis. 2002;17:111–117
  3. Tomasulo PA, Anderson AJ, Paluso MB, et al. A study of criteria for blood donor deferral. Transfusion. 1980;20:511–518
  4. Eder AF, Bianco C, Rossmann S, et al. International disparities in whole blood donor deferral criteria intended to protect donors. Transfusion. 2008;48:302A
  5. Newman BH. Blood donor complications after whole-blood donation. Current Opin Hematol. 2004;11:321–322
  6. Wiltbank TB, Giordano GF. The safety profile of automated collections: An analysis of more than 1 million collections. Transfusion. 2007;47:1002–1005
  7. Eder AF, Dy BA, Kennedy JM, et al. The American Red Cross donor hemovigilance program: Complications of blood donation reported in 2006. Transfusion. 2008;48:1809–1819
  8. Bianco C, Brittenham G, Gilcher RO, et al. Maintaining iron balance in women blood donors of childbearing age: Summary of a workshop. Transfusion. 2002;42:798–805
  9. Custer B, Chinn A, Hirschler NV, et al. The consequences of temporary deferral on future of whole blood donation. Transfusion. 2007;47:1514–1523
  10. Halperin D, Baetens J, Newman B. The effect of short-term, temporary deferral on future blood donation. Transfusion. 1998;38:181–183
  11. Zou S, Musavi F, Notari EP, et al. Donor deferral and resulting donor loss at the American Red Cross Blood Services, 2001 through 2006. Transfusion. 2008;48:2531–2539
  12. France CR, France JL, Roussos M, et al. Mild reactions to blood donation predict a decreased likelihood of donor return. Transfus Apher Sci. 2004;30:17–22
  13. Fridey JL, Townsend MJ, Kessler DA, et al. A question of clarity: Redesigning the American Association of Blood Banks blood Donor History Questionnaire—A chronology and model for donor screening. Transfus Med Rev. 2007;21:181–204
  14. Busch MP, Young MJ, Samson SM, et al. Risk of human immunodeficiency virus transmission by blood transfusions prior to the implementation of HIV antibody screening in the San Francisco Bay Area. Transfusion. 1991;31:4–11
  15. FDA Draft Guidance . Acceptable full-length Donor History Questionnaire and accompanying materials for use in screening human donors of blood and blood components. Available at: http://www.fda.gov/cber/gdlns/donorhistques.htm
  16. AABB . Donor History Questionnaire. Available at: http://www.aabb.org/Content/Donate_Blood/Donor_History_Questionnaires/AABB_Blood_Donor_History_Questionnaire
  17. Department of Health and Human Services , Food and Drug Administration . Requirements for Human Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use; Proposed Rule Federal Register: November 8, 2007 (Volume 72, Number 216) 21 CFR Parts 606, 610, et al.. Available at: http://www.fda.gov/cber/rules/reqbldtrans.htm
  18. Federal Docket Management System. Public Comment on Docket Number 2006N-0221, 8 November 2007: Requirements for Human Blood and Blood Components Intended for Further Manufacturing Use, Proposed Rule. Available at: http://www.regulations.gov/search/search_results.jsp?css=0&&Ntk=All&Ntx=mode+matchall&Ne=2+8+11+8053+8054+8098+8074+8066+8084+8055&N=0&Ntt=2006N-0221&sid=11E8C2529BD9
  19. O'Brien SF, Ram SS, Vamvakas EC, et al. The Canadian Blood Donor Health Assessment Questionnaire: Lessons from history, application of cognitive science principles, and recommendations for change. Transfus Med Rev. 2007;21:205–222
  20. Seitz R, Heiden M, Nübling CM, et al. The harmonization of the regulation of blood products: A European perspective. Vox Sang. 2008;94:267–276
  21. Council of Europe . Guide to the Preparation, Use and Quality Assurance of Blood Components. 14th ed. Strasbourg: Council of Europe Publishing; 2008;
  22. The Commission of European Communities . Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 Setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC. Official Journal of the European Journal. Available at: http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:033:0030:0040:EN:PDF
  23. The Commission of European Communities: Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components. Official Journal of the European Union. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:091:0025:0039:EN:PDF
  24. Follea GF. Donor selection criteria throughout Europe. Vox Sang. 2005;89:113–209
  25. Chiavetta JA, Deeks S, Goldman M, et al. Proceedings of a consensus conference: blood-borne HIV and hepatitis—Optimizing the donor selection process. Transfus Med Rev. 2003;17:1–30
  26. Poles FC, Boycott M. Syncope in blood donors. Lancet. 1942;240:531–535
  27. Trouern-Trend JJ, Cable RG, Badon SJ, et al. A case-controlled multicenter study of vasovagal reactions in blood donors: Influence of sex, age, donation status, weight, blood pressure, and pulse. Transfusion. 1999;39:316–320
  28. Newman BH, Satz SL, Janowicz NM, et al. Donor reactions in high-school donors: The effects of sex, weight, and collection volume. Transfusion. 2006;46:284–288
  29. Eder AF, Hillyer CD, Dy BA, et al. Adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds. JAMA. 2008;299:2279–2286
  30. Wiltbank TB, Giordano GF, Kamel H, et al. Faint and prefaint reactions in whole-blood donors: An analysis of predonation measurement and their predictive value. Transfusion. 2008;48:1799–1808
  31. Rios JA, Fang JY, Spencer B, et al. Relationship between body mass index and other factors in blood donors having vasovagal reactions. Transfusion. 2008;48:30A;[Suppl]
  32. Price TH. Requirements for allogeneic qualification. Standards for Blood Banks and Transfusion Services. 25th ed. Bethesda (Md): AABB Press; 2006;
  33. Eder A, Kamel H, France C, et al. Recommendations to minimize the risk of reactions and injuries among adolescent blood donors. AABB Bulletin 08-04, (Appendix1). Available at: http://www.aabb.org/Content/Members_Area/Association_Bulletins/ab08-04.htm
  34. France CR, Menitove JE. Mitigating adverse reactions in young donors. Transfusion. 2008;48:1774–1776
  35. Goldman M, Fournier E, Cameron-Choi K, et al. Effect of changing the age criteria for blood donors. Vox Sang. 2007;92:368–372
  36. Shehata N, Kusano R, Hannach , et al. Reaction rates in allogeneic donors. Transfusion Med. 2004;4:327–333
  37. Ali AM, Goldsmith CH, McAvoy AT, et al. A prospective study evaluating the lowering of hemoglobin standards for blood donors. Transfusion. 1989;29:268–272
  38. Pi DW, Krikler SH, Sparling TG, et al. Reappraisal of optimal hemoglobin standards for female blood donors in Canada. Transfusion. 1994;34:7–10
  39. Beutler E, Waalen J. The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration?. Blood. 2006;107:1747–1750
  40. Fulwood F, Johnson CI, Bryner JD, et al. Hematological and nutritional biochemistry reference data for persons 6 months-74 years of age; United States, 1976-1980. Vital and health statistics, Series 11, No 232. CHHS Publication number (PYS) 83-1682. Washington (DC): Public Health Service, National Center for Heath Statistics, Government Printing Office; 1982;
  41. Sempos CT, Looker AC, Gillum RF, et al. Body iron stores and the risk of coronary heart disease. N Engl J Med. 1994;330:1119–1124
  42. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion. 2002;42:1135–1139
  43. Ascherio A, Rimm EB, Giovannucci E, et al. Blood donations and risk of coronary heart disease in men. Circulation. 2001;103:52–57
  44. Murray-Kolb LE, Beard JL. Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr. 2007;85:778–787
  45. Page EA, Harrison JF, Jaldow EJ, et al. Impairment of short-term memory associated with low iron stores in a volunteer multidose plateletpheresis donor. Transfus Med. 2008;18:312–314
  46. Farrugia A. Iron and blood donation—An under recognized safety issue. Dev Biol. 2007;127:137–146
  47. Simon TL, Garry PJ, Hooper EM. Iron stores in blood donors. J Am Med Assoc. 1981;245:2038–2043
  48. Pickering TG, Hall JE, Appel LJ, et al. Recommendation for blood pressure measurement in humans and experimental animals. Circulation. 2005;111:697–716
  49. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560–2571
  50. Tierney WM, Brunt M, Kesterson J, et al. Quantifying risk of adverse clinical events with one set of vital signs among primary care patients with hypertension. Ann Fam Med. 2004;2:209–217
  51. Newman B, Siegried B, Haley NR, et al. Quantitative study of contributing factors to vasovagal donor reaction rates in eight blood centers. (abstract) Transfusion. 2008;48:58A;[Suppl 2]
  52. AHA Statistical Update . Heart disease and stroke statistics 2007 update. Circulation. 2007;115:e69–e171
  53. Agency for Healthcare Research and Quality, Medical Expenditure Panel Survey. Available at: http://www.meps.ahrq.gov
  54. Strupp A. Blood donors with cardiovascular disease. In:  Eder A,  Bianco C editor. Screening Blood Donors: Science Reason and the Donor History Questionnaire. Bethesda (Md): AABB Press; 2007;p. 31–55
  55. Thomas MJG, Gillon J, Desmond MJ. Preoperative autologous blood donation. Transfusion. 1996;36:633–639
  56. Hillyer CD, Hart KK, Lackey DA, et al. Comparable safety of blood collection in “high-risk” autologous donors versus non–high-risk autologous and directed donors in a hospital setting. Am J Clin Pathol. 1994;102:275–277
  57. Aubuchon JP, Popovsky MA. The safety of preoperative autologous blood donation in the nonhospital setting. Transfusion. 1991;31:513–517
  58. Domen R, Hnat H, Panasiuk M. Autologous blood donation by patients with cardiovascular disease. Vox Sang. 1992;63:137
  59. McCarthy LJ, Danielson C, Pugh M, et al. Should cardiac disease prevent autologous blood donation?. Transfus Sci. 1997;18:81–83
  60. Pisciotto P, Sataro P, Blumberg N. Incidence of adverse reactions in blood donors taking antihypertensive medications. Transfusion. 1982;22:530–531
  61. Eder A. Blood donors with a history of cancer. In:  Eder A,  Bianco C editor. Screening Blood Donors: Science Reason and the Donor History Questionnaire. Bethesda (Md): AABB Press; 2007;p. 77–92
  62. US. Food and Drug Administration, Center for Biologics Evaluation and Research, Blood Donor Suitability Workshop, December 9, 1999. Available at: http://www.fda.gov/cber/minutes/donsuit120999.htm
  63. Edgren G, Hjalgrim H, Reilly M, et al. Risk of cancer after blood transfusion from donors with subclinical cancer: A retrospective cohort study. Lancet. 2007;369:1724–1730
  64. Purdy E, Jensen K, Perry E, et al. Success of reinstating donors previously deferred five years for history of cancer. Transfusion. 2005;45:174A
  65. Fernandez-Campa G, Bernardo M, Chiin T, et al. The evaluation of blood donor deferral causes. Vox Sang. 2007;93:63
  66. Melanson SEF, Stowell CP, Flood JG, et al. Does blood donor history accurately reflect the use of prescription medications? A comparison of donor history and serum toxicologic analysis. Transfusion. 2006;46:1402–1407
  67. Gu Q, Paulose-Ram R, Dillon C, et al. Antihypertensive medication use among US adults with hypertension. Circulation. 2006;113:213–221
  68. Lavoie P, Charest L, Germain M, et al. Severe reactions among autologous donors. Transfusion. 1999;39:30S
  69. Land KJ. Medications and Vaccines. In:  Eder A,  Bianco C editor. Screening Blood Donors: Science, Reason and the Donor History Questionnaire. Bethesda (Md): AABB Press; 2007;p. 93–120
  70. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15–25
  71. National Institutes of Diabetes and Digestive and Kidney Diseases, NIH, National Diabetes Statistics, 2007, National Diabetes Information Clearinghouse. http://diabetes.niddk.nih.gov/dm/pubs/statistics/Accessed February 8, 2009
  72. Lampeter EF, McCann SR, Kolb H. Transfer of diabetes type 1 by bone-marrow transplantation. Lancet. 1998;351:568–569
  73. Lee TH, Paglieroni T, Ohto H, et al. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: Frequent long-term microchimerism in severe trauma patients. Blood. 1999;93:3127–3139
  74. Artlett CM. Microchimerism in health and disease. Curr Mol Med. 2002;2:525–535
  75. International Forum . Haemovigilance. Vox Sang. 2006;90:207–241
  76. Jorgenson J and the Working Group on Complications of Blood Donation. Standard for surveillance of complications related to blood donation. 2008. International Society of Blood Transfusion, Working Party on Haemovigilance, European Haemovigilance Network. http://www.isbt-web.org/members_only/files/society/StandardSurveillanceDOCO.pdfAccessed, February 7, 2009
  77. Caffrey EA: Adverse events in whole blood donors. Blood matters: Quarterly information for hospitals served by the National Blood Service (newsletter). 2006;19:3-4 http://hospital.blood.co.uk/library/blood_matters/index.asp Accessed February 7, 2009
  78. Haemovigilance Working Group. TROLL—the haemovigilance annual report on blood transfusion and donation in Norway. http://www.hemovigilans.no/docs/haemovigilance-english2004%20060901.doc2004;Accessed February 7, 2009

PII: S0887-7963(09)00029-7

doi: 10.1016/j.tmrv.2009.03.003

Transfusion Medicine Reviews
Volume 23, Issue 3 , Pages 205-220 , July 2009

Article Tools

* Image Usage & Resolution